Navigation Links
AbbVie's Investigational HCV Regimen Receives Breakthrough Therapy Designation from the U.S. Food and Drug Administration
Date:5/6/2013

NORTH CHICAGO, Ill., May 6, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that its investigational direct-acting antiviral (DAA) combination with and without ribavirin for the treatment of genotype 1 (GT1) hepatitis C virus (HCV) infection has been designated as a Breakthrough Therapy by the U.S. Food and Drug Administration (FDA).

The designation is based, in part, on positive data from AbbVie's clinical development program, including the Phase 2b clinical trial M11-652, known as "Aviator." The Aviator study was conducted in 571 patients infected with HCV GT1.  Results from the treatment arms evaluating ABT-450/r + ABT-267 + ABT-333 with and without ribavirin demonstrated that the regimen provided high sustained viral response rates (SVR) with 12 weeks of therapy in patients who had not been previously treated (treatment naive) and in those who had failed prior therapy with pegylated interferon and ribavirin (null responders), regardless of sex, HCV subtype, stage of fibrosis, viral load or IL28B genotype.  

According to the FDA, Breakthrough Therapy designation is intended to expedite the development and review of drugs for serious or life-threatening conditions. The criteria for Breakthrough Therapy designation includes preliminary clinical evidence demonstrating a drug may have substantial improvement on at least one clinically significant endpoint compared to available therapy. A Breakthrough Therapy designation conveys all of the fast track program features, as well as more intensive FDA guidance on an efficient drug development program.(1)

"AbbVie is pleased that the FDA has granted Breakthrough Therapy designation to our 3-DAA combination with and without ribavirin. We feel it reflects the potential of this regimen to be important in the treatment of HCV," said John M
'/>"/>

SOURCE AbbVie
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Bayer Initiates Phase III Trial of Investigational Inhaled Amikacin Solution (BAY41-6551T) in Mechanically Ventilated Patients with Gram-negative Pneumonia
2. Bayers Investigational Riociguat Granted U.S. FDA Priority Review for Pulmonary Arterial Hypertension and Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension
3. Positive Preclinical Data for NKTR-214, an Investigational Cancer Immunotherapy Targeting the IL-2 Receptor Complex, Presented at AACR Annual Meeting 2013
4. European Medicines Agency accepts marketing authorization application for Boehringer Ingelheim and Eli Lilly and Companys empagliflozin*, an investigational type 2 diabetes treatment
5. Boehringer Ingelheim and Eli Lilly and Company submit new drug application to FDA for empagliflozin, an investigational type 2 diabetes treatment
6. Genocea Publishes Preclinical Data For Investigational Vaccine Candidate For HSV-2
7. Noven Announces FDA Advisory Committee Vote on Investigational Low-Dose Mesylate Salt of Paroxetine (LDMP) for Vasomotor Symptoms Associated with Menopause
8. Scioderms Investigational New Drug (IND) Application for SD-101 for Treatment of Epidermolysis Bullosa (EB) Allowed by the FDA
9. BHR Pharma Investigational Traumatic Brain Injury Treatment Receives European Medicines Agency Orphan Medicinal Product Designation
10. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
11. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... May 1, 2015 Braeburn Pharmaceuticals ... current therapeutic focus beyond addiction and pain ... disorders. Braeburn has acquired an implantable, six-month ... risperidone for treatment of schizophrenia from Endo ... global rights to other potential applications of ...
(Date:5/1/2015)... May 1, 2015  Boston Scientific Corporation (NYSE: ... business momentum and long-term growth strategies at a meeting ... York City . President and Chief Executive Officer ... the company has to bring forward meaningful innovation to ... and deliver shareholder value. "We are ...
(Date:5/1/2015)... Cambrex Corporation (NYSE: CBM ) reports results for the ... , Sales increased 18% compared to the first ... driven by Innovator products and Controlled Substances. , EBITDA ... quarter of 2014. , GAAP Diluted EPS from continuing ... year and Adjusted Diluted EPS was $0.29 compared to $0.07 ...
Breaking Medicine Technology:Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments 2Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments 3Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments 4Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 2Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 3Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 4Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 5Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 6Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 7Cambrex Reports First Quarter 2015 Financial Results 2Cambrex Reports First Quarter 2015 Financial Results 3Cambrex Reports First Quarter 2015 Financial Results 4Cambrex Reports First Quarter 2015 Financial Results 5Cambrex Reports First Quarter 2015 Financial Results 6Cambrex Reports First Quarter 2015 Financial Results 7Cambrex Reports First Quarter 2015 Financial Results 8Cambrex Reports First Quarter 2015 Financial Results 9Cambrex Reports First Quarter 2015 Financial Results 10Cambrex Reports First Quarter 2015 Financial Results 11
... drug used to treat erectile dysfunction and pulmonary ... and young adults with congenital heart disease to ... exercise performance during stress testing in patients with ... Children,s Hospital of Philadelphia. This study ...
... American Medical Systems® (AMS) (Nasdaq: AMMD ), ... male and female pelvic health, today announced the results ... Anterior and Apical Prolapse Repair System. The pelvic organ ... stage pelvic support, was implemented in the study and ...
Cached Medicine Technology:Exercise Performance in Children and Young Adults with Single Ventricle Heart Disease Improves with Use of Drug for Erectile Dysfunction 2Exercise Performance in Children and Young Adults with Single Ventricle Heart Disease Improves with Use of Drug for Erectile Dysfunction 3Six-Month Prospective Multi-Center Study Reports Efficacy Rates for AMS' Elevate Anterior and Apical Prolapse Repair System 2
(Date:5/3/2015)... 03, 2015 “ BolehVPN ” was featured ... features the latest and coolest technology products available to consumers. ... conducted the review and shared with viewers how to protect ... these days is on computers and even more so online. ... meet people all over the world. In terms of work, ...
(Date:5/3/2015)... is not too late to register to take part in the ... Been in Arnold, Missouri on May 9, 2015. Family and ... loving memory. It has benefited the renowned Brain Aneurysm Foundation each ... suffered a brain aneurysm . After two operations and five ... designed to serve as a remembrance of her and to help ...
(Date:5/2/2015)... 02, 2015 Vancouver fencing company, QS Fencing, ... valuable advice to prospective clients related to their questions on ... install railings around their decks and patios. While that seems ... pop up once the person rolls up their sleeve to ... a railing in finding a gate that matches it. , ...
(Date:5/2/2015)... 2015 We are pleased to announce ... Center as one of the Top Workplaces of 2015. ... addiction treatment field for their ethics and standards of ... to continue their educational efforts. The Delray Recovery Center ... forgetting their purpose – to help individuals heal from ...
(Date:5/2/2015)... As a nonsurgical staple in the ... neck and décolleté, radiofrequency energy is proving to ... the success of vulvovaginal rejuvenation. In a pilot ... ThermiGyn’s Women’s Health Clinical Advisory Board Chairman Red ... temperature controlled radio frequency, specifically that of ThermiVa, ...
Breaking Medicine News(10 mins):Health News:A Method to Keep Private Information Secure was Featured on NewsWatch Television 2Health News:Renowned Brain Aneurysm Foundation to Benefit from Arnold, Missouri’s 3rd Annual Brain Aneurysm Walk in Memory of Lissa Anne Been 2Health News:Professional Staff at QS Fencing Company Now Provides Advice on Railings and Gates 2Health News:The Delray Recovery Center Named 2015 Top Workplace 2Health News:Study Demonstrates Efficacy of Temperature Controlled Radiofrequency for Vulvovaginal Laxity 2Health News:Study Demonstrates Efficacy of Temperature Controlled Radiofrequency for Vulvovaginal Laxity 3
... Americans United for Life,(AUL) today filed an amicus ... and should be upheld., AUL Staff Counsel Mailee ... has affirmed that states have a significant interest in,protecting ... That is,precisely what the Act does.", AUL Vice ...
... Two new guides to,help consumers and clinicians prevent and ... Department of Health and Human Services, Agency,for Healthcare Research ... but deep vein thrombosis, a blood clot,that forms in ... the lower leg or,thigh, is a potentially deadly medical ...
... for Global Health (HIGH) has been selected to receive ... from the National Institutes of Health,s Fogarty International Center., ... additional $300,000 grant from the University and support HIGH,s ... The grant will fund the Fostering Opportunities for Nutrition ...
... atypical antipsychotic medications were no more effective than an ... and may lead to more metabolic side effects, according ... of Health,s National Institute of Mental Health (NIMH). The ... 2008, in the American Journal of Psychiatry . ...
... in affected areas, WASHINGTON, Sept. 14 One ... a Category 2 hurricane, the American,Red Cross is providing ... of residents affected by the powerful storm. Although it ... storm rain and,high winds throughout Arkansas as it heads ...
... Concussion most common danger, expert says, so head, face ... News) -- Children who play school sports need to ... injuries, emphasizes the director of sports medicine at Cincinnati ... recommends the following equipment for young athletes: , ...
Cached Medicine News:Health News:VA Partial Birth Abortion Infanticide Act Constitutional, Should Be Upheld, Argues Americans United for Life Brief 2Health News:AHRQ Releases Two New Resources to Help Consumers and Clinicians Prevent Dangerous Blood Clots 2Health News:AHRQ Releases Two New Resources to Help Consumers and Clinicians Prevent Dangerous Blood Clots 3Health News:Harvard University recipient of Global Health Nutrition grant 2Health News:Newer antipsychotics no better than older drug in treating child and adolescent schizophrenia 2Health News:Red Cross Urges Safety in Wake of Hurricane Ike 2Health News:Red Cross Urges Safety in Wake of Hurricane Ike 3Health News:Safety Gear a Must to Prevent Kids' Sports Injuries 2
... well as humidification, try Flo-Mist™., ,Flo-Mist™, ... continuous medication nebulizer (CMN), engineered to deliver ... ml reservoir and jet flow design allow ... medication delivery at 25 ml/hr. Particles are ...
... Innovators in Anesthesia and Respiratory Products, ... medical devices for Anesthesia and Respiratory professionals. ... products that enhance the clinician's ability to ... attention to the bottom line. , ...
... Why design a nebulizer for this age ... coordinating inspiratory effort with actuation of an MDI. ... minimum inspiratory flow rate to achieve efficiency. , ... efficiency. , ,Blowby techniques often used for ...
... The new PARI TREK™ Compact Compressor ... take their aerosol treatments anywhere and everywhere. ... powerful. Three versatile power source optionsworldwide AC ... and rechargeable battery, permit patients the freedom ...
Medicine Products: